COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab

BACKGROUND: Alemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and there is still lack of evidence to guide MS practice. METHODS/RESULTS: We describe the clinical and immunological evolution of two MS patients...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Mult Scler Relat Disord
Huvudupphovsmän: Fernández-Díaz, Eva, Gracia-Gil, Julia, García-García, Jose Gregorio, Palao, María, Romero-Sánchez, Carlos M, Segura, Tomás
Materialtyp: Artigo
Språk:Inglês
Publicerad: Elsevier B.V. 2020
Ämnen:
Correspondence
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7366111/
https://ncbi.nlm.nih.gov/pubmed/32711297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2020.102402
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk